Ischemia Reperfusion Injury - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Pipeline Review, H1 2019’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury

- The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects

- The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akashi Therapeutics Inc

Argenx SE

Balmes Transplantation SAS

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

Cellmid Ltd

CFM Pharma Holding BV

Conatus Pharmaceuticals ...

Akashi Therapeutics Inc

Argenx SE

Balmes Transplantation SAS

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

Cellmid Ltd

CFM Pharma Holding BV

Conatus Pharmaceuticals Inc

Corline Biomedical AB

Gilead Sciences Inc

Glucox Biotech AB

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

MallInckrodt Plc

NovelMed Therapeutics Inc

Pfizer Inc

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Stealth BioTherapeutics Corp

Table of Contents

Table of Contents

Introduction

Ischemia Reperfusion Injury – Overview

Ischemia Reperfusion Injury – Therapeutics Development

Ischemia Reperfusion Injury – Therapeutics Assessment

Ischemia Reperfusion Injury – Companies Involved in Therapeutics ...

Table of Contents

Introduction

Ischemia Reperfusion Injury – Overview

Ischemia Reperfusion Injury – Therapeutics Development

Ischemia Reperfusion Injury – Therapeutics Assessment

Ischemia Reperfusion Injury – Companies Involved in Therapeutics Development

Ischemia Reperfusion Injury – Drug Profiles

Ischemia Reperfusion Injury – Dormant Projects

Ischemia Reperfusion Injury – Discontinued Products

Ischemia Reperfusion Injury – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Ischemia Reperfusion Injury – Pipeline by Akashi Therapeutics Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Argenx SE, H1 2019

Ischemia Reperfusion Injury – Pipeline by Balmes Transplantation SAS, H1 2019

Ischemia Reperfusion Injury – Pipeline by Bolder Biotechnology Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Catalyst Biosciences Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Celdara Medical LLC, H1 2019

Ischemia Reperfusion Injury – Pipeline by Cellmid Ltd, H1 2019

Ischemia Reperfusion Injury – Pipeline by CFM Pharma Holding BV, H1 2019

Ischemia Reperfusion Injury – Pipeline by Conatus Pharmaceuticals Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Corline Biomedical AB, H1 2019

Ischemia Reperfusion Injury – Pipeline by Gilead Sciences Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Glucox Biotech AB, H1 2019

Ischemia Reperfusion Injury – Pipeline by Ischemix Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019

Ischemia Reperfusion Injury – Pipeline by LG Chem Ltd, H1 2019

Ischemia Reperfusion Injury – Pipeline by MallInckrodt Plc, H1 2019

Ischemia Reperfusion Injury – Pipeline by NovelMed Therapeutics Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Pfizer Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Radikal Therapeutics Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by Reata Pharmaceuticals Inc, H1 2019

Ischemia Reperfusion Injury – Pipeline by SBI Pharmaceuticals Co Ltd, H1 2019

Ischemia Reperfusion Injury – Pipeline by Stealth BioTherapeutics Corp, H1 2019

Ischemia Reperfusion Injury – Dormant Projects, H1 2019

Ischemia Reperfusion Injury – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports